A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue

• Published in: Biomedicine & pharmacotherapy Vol. 172; p. 116220
• Main Authors: Sheng, Ren, Li, Yining, Wu, Yexiang, Liu, Chang, Wang, Weizhi, Han, Xiaowan, Li, Yinghong, Lei, Lijuan, Jiang, Xinhai, Zhang, Yuyan, Zhang, Yuhao, Li, Shunwang, Hong, Bin, Liu, Chao, Xu, Yanni, Si, Shuyi
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.03.2024
• Subjects: ABCA1; Diabetic dyslipidemia; Pan-PPAR agonist; T2DM; GNG; T2DM; RCT; RGZ; ITT; Pan-PPAR agonist; FBG; Irs; ORO; LBD; DEGs; PPAR; RNA-seq; Diabetic dyslipidemia; ApoE; KKAy; DKD; HFHG; ABCA1; H&E; InsR; qRT-PCR; eWAT; CVD; GSIS; OGTT

Type 2 diabetes mellitus (T2DM) is a common chronic metabolic disease. Peroxisome proliferator-activated receptors (PPARs) play crucial roles in regulating glucolipid metabolism. Previous studies showed that E17241 could ameliorate atherosclerosis and lower fasting blood glucose levels in ApoE−/− mi...